PMC9626227_01
Mucocutaneous involvement in the initial presentation.
CRIHEM2022-3641474.001.jpg
PMC9626227_01_CRIHEM2022-3641474.001.jpg
fig1
A 49-year-old male presented with acute-onset painful oral, genital, and ocular erosions along with dusky erythema and flaccid bullae on his trunk, scalp, and intertriginous areas (Figures 1 and 2).
Axillary involvement in the initial presentation.
CRIHEM2022-3641474.002.jpg
PMC9626227_01_CRIHEM2022-3641474.002.jpg
fig2
A 49-year-old male presented with acute-onset painful oral, genital, and ocular erosions along with dusky erythema and flaccid bullae on his trunk, scalp, and intertriginous areas (Figures 1 and 2).
CT Abdomen and Pelvis with contrast showing enlarged preaortic lymph node (measured as 8 x 4 cm on axial view).
CRIHEM2022-3641474.003.jpg
PMC9626227_01_CRIHEM2022-3641474.003.jpg
fig3
Computerized tomography (CT) demonstrated an eleven-centimeter preaortic lymph node in the abdomen (Figures 3 and 4), along with scattered retroperitoneal and mesenteric lymphadenopathy, Positron emission tomography (PET-CT) confirmed increased fluorodeoxyglucose (FDG) uptake in these areas.
The same mass that was visualized in Figure 3, measured as 11.7 cm on sagittal view of CT.
CRIHEM2022-3641474.004.jpg
PMC9626227_01_CRIHEM2022-3641474.004.jpg
fig4
Computerized tomography (CT) demonstrated an eleven-centimeter preaortic lymph node in the abdomen (Figures 3 and 4), along with scattered retroperitoneal and mesenteric lymphadenopathy, Positron emission tomography (PET-CT) confirmed increased fluorodeoxyglucose (FDG) uptake in these areas.
Resolution of axillary involvement after two months of treatment.
CRIHEM2022-3641474.005.jpg
PMC9626227_01_CRIHEM2022-3641474.005.jpg
fig5
He had a resolution of his skin lesions after two months of treatment (Figure 5), but his oral lesions persisted.
Resolution of oral and mucocutaneous involvement after four months of treatment.
CRIHEM2022-3641474.006.jpg
PMC9626227_01_CRIHEM2022-3641474.006.jpg
fig6
His oral lesions ultimately resolved about four months after the initiation of treatment (Figure 6).